Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of November 2025, with the report issued on November 19, 2025. The document details a specific corporate action regarding the transfer of treasury shares rather than a periodic financial performance report.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the share transaction:
- Shares Transferred: 22,000,000 Ordinary Shares.
- Consideration Received: £17.995 per Ordinary Share.
- Funding Source: A loan from GlaxoSmithKline Services Unlimited.
Material Changes
Following the transfer of shares to the GlaxoSmithKline Employee Trust (Jersey Trust) on November 18, 2025, the company's capital structure changed as follows:
- Treasury Shares Held: Reduced to 234,819,844 Ordinary Shares.
- Shares in Issue: 4,080,611,266 Ordinary Shares (excluding Treasury Shares).
- Total Voting Rights: 4,080,611,266.
- Treasury Voting Percentage: 5.75% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was executed to satisfy awards under the Deferred Annual Bonus Plan, Performance Share Plan, and Share Value Plan. The announcement was made in accordance with UK Listing Rule 9.8.2 and DTR 5.5.1R.
Investor Verification Checklist
- Verify the updated total number of voting rights (4,080,611,266) for disclosure threshold calculations under FCA rules.
- Confirm the percentage of voting rights attributable to Treasury Shares (5.75%).
- Note that the consideration for the share transfer was funded via an intercompany loan.
- Understand that this filing does not contain updated financial results or operational metrics.